Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Antibe Holdings

<< Previous

Bullboard Posts

Next >>

Post by Ryeman40on Dec 18, 2020 11:45pm

268 Views

Post# 32146289

Antibe Holdings

I'm wondering if a couple of the new "partnering advisory team" had some input with the new press release.
Going forward should clear up any confusion with the unifying of IP.
Antibe Holdings- CSO of Antibe Therapeutics John Wallace owns 16.7% and Dan Legault is President and CEO.
Current assignee is Antibe Holdings which means they own all patents.
This makes for some dry reading but some of the future IP's i knew and some where a surprise.
https://patents.google.com/patent/US8541398B2/en